ArticleDiabetes, obesity & metabolism2021

Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.

Simone Bastrup Israelsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.